Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Conjugate Vaccine Market Revenue Growth On Track For A 12.8% CAGR Through 2030
The conjugate vaccine market size has experienced substantial expansion recently. It is projected to increase from $21.26 billion in 2025 to $23.84 billion by 2026, achieving a compound annual growth rate (CAGR) of 12.1%. Historically, this growth can be ascribed to government-led immunization initiatives, the high prevalence of bacterial infections, support from global health organizations, the proven efficacy of conjugate vaccines, and an expanding pediatric population.
The conjugate vaccine market is projected to experience substantial expansion over the upcoming years. It is anticipated to reach a valuation of $38.54 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.8%. This anticipated growth during the forecast period can be primarily attributed to several factors, including an increasing demand for combination vaccines, the broadening of adult vaccination programs, augmented funding for vaccine research and development, a heightened focus on antimicrobial resistance, and enhancements in cold chain infrastructure. Key trends expected within this period encompass the expansion of pediatric immunization initiatives, a growing embrace of multivalent conjugate vaccines, an intensified emphasis on long-term immunogenicity, an increase in public-private collaborations for vaccines, and progress in carrier protein technologies.
Get A Free Sample Report With In-Depth Market Insights:
Conjugate Vaccine Market Expansion Drivers: What’s Shaping Future Growth?
The conjugate vaccine market is projected to experience growth due to the escalating incidence of infectious diseases. These conditions are health ailments caused by pathogenic microorganisms, including bacteria, viruses, parasites, or fungi, which can be transmitted directly or indirectly between people, from animals to humans, or through environmental factors. Conjugate vaccines are crucial for preventing infectious diseases stemming from certain bacteria, particularly in vulnerable demographics such as infants and young children. For instance, data from the Centers for Disease Control and Prevention, a US government agency, indicates that tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, showing an increase of 1,295 cases. Additionally, the incidence rate rose from 2.5 per 100,000 individuals in 2022 to 2.9 in 2023. Thus, the increasing occurrence of infectious diseases is a key driver for the expansion of the conjugate vaccine market.
Conjugate Vaccine Market Segment Landscape And Growth Outlook
The conjugate vaccine market covered in this report is segmented –
1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users
Conjugate Vaccine Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies in the conjugate vaccine market are prioritizing the creation of next-generation conjugate vaccines to deliver more extensive protection against various pneumococcal serotypes, thereby lessening the disease burden among susceptible demographics. These advanced conjugate vaccines operate by linking bacterial polysaccharides to carrier proteins to enhance the immune response, particularly in infants and immunocompromised individuals, providing superior protection, extended immunity, and increased efficacy compared to conventional vaccines. For example, in August 2025, Pfizer Ltd., an India-based pharmaceutical company, unveiled its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., PCV20, for adults in India, thereby bolstering its conjugate vaccine offerings by ensuring broader defense against pneumococcal disease and aiding in improved public health outcomes.
Conjugate Vaccine Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the conjugate vaccine market are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus
View The Full Conjugate Vaccine Market Report:
Conjugate Vaccine Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the global conjugate vaccine market in 2025. The regions covered in the conjugate vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
